Duration of serologic response to three viral antigens in cats

Journal of the American Veterinary Medical Association

Volumn 224, Issue 1, 2004, Pages 61-66

  Mouzin, Douglas E ^a   Lorenzen, Marianne J ^a   Haworth, John D ^a   King, Vickie L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN; VIRUS VACCINE;

ADOLESCENT; AGED; ALOPECIA; ANOREXIA; ANTIBODY TITER; CALICIVIRUS; CAT; CAT DISEASE; CONTROLLED STUDY; FELINE PANLEUKOPENIA VIRUS; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION TEST; HEMATURIA; HERPES VIRUS; LETHARGY; LIFESTYLE; MALE; NONHUMAN; QUESTIONNAIRE; REVACCINATION; REVIEW; RISK ASSESSMENT; SEROLOGY; VIRUS INFECTION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CALICIVIRUS, FELINE; CAT DISEASES; CATS; FELINE PANLEUKOPENIA VIRUS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HERPESVIRIDAE; IMMUNIZATION, SECONDARY; MALE; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES; VIRAL VACCINES; VIRUS DISEASES;

ANIMALIA; CALICIVIRIDAE; FELIDAE; FELINE CALICIVIRUS; FELINE HERPESVIRUS 1; FELINE PANLEUKOPENIA VIRUS; FELIS CATUS; HERPESVIRIDAE;

EID: 0346881266     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2004.224.61     Document Type: Review

References (20)

1. Hendrick MJ, Goldschmidt MH, Shofer FS, et al. Postvaccinal sarcomas in the cat: epidemiological and electron probe microanalytical identification of aluminum. Cancer Res 1992;52:5391-5394.
2. Kass PH, Barnes WG Jr, Spangler WL, et al. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 1993;203:396-405.
3. Richards J, Rodan I, Elston T, et al. Feline vaccine selection and administration. Compend Contin Educ Pract Vet 2001;23:71-80.
4. Klingborg DJ, Hustead DR, Curry-Galvin EA, et al. AVMA Council on Biologic and Therapeutic Agents' report on cat and dog vaccines. J Am Vet Med Assoc 2002;221:1401-1407.
5. Schultz RD. Current and future canine and feline vaccination programs. Vet Med 1998;93:233-254.
6. Coyne MJ, Postorino Reeves NC, Rosen DK. Estimated prevalence of injection-site sarcomas in cats during 1992. J Am Vet Med Assoc 1997;210:249-251.
7. Gobar GM, Kass PH. World Wide Web-based survey of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc 2002;220:1477-1482.
8. Greene CE, Schultz RD, Ford RB. Canine vaccination. Vet Clin North Am Small Anim Pract 2001;31:473-492.
9. Scott-Moncrieff JC, Azcona-Olivera J, Glickman NW, et al. Evaluation of antithyroglobulin antibodies after routine vaccination in pet and research dogs. J Am Vet Med Assoc 2002;221;515-521.
10. Feline vaccine liability and management. Comp Contin Educ Pract Vet 2001;23:116-126, 165.
11. Coyne MJ, Burr JHH, Yule TD, et al. Duration of immunity in dogs after vaccination or naturally acquired infection. Vet Rec 2001;149:509-515.
12. Lappin MR, Andrews J, Simpson D, et al. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. J Am Vet Med Assoc 2002;220:38-42.
13. McCaw DL, Thompson M, Tate D, et al. Serum distemper virus and parvovirus antibody titers among dogs brought to a veterinary hospital for revaccination. J Am Vet Med Assoc 1998;213:72-75.
14. Scott FW, Geissinger CM. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine. Am J Vet Res 1999;60:652-658.
15. Tizard I, Ni Y. Use of serologic testing to assess immune status of companion animals. J Am Vet Med Assoc 1998;213:54-60.
16. Twark L, Dodds WJ. Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. J Am Vet Med Assoc 2000;217:1021-1024.
17. Carmichael LE. Canine viral vaccines at a turning point-a personal perspective. Adv Vet Med 1999;41:289-307.
18. Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. "Endgame" issues for the global polio eradication initiative. Clin Infect Dis 2002;34:72-77.
19. Hsia EC, Chung JB, Schwartz JS, et al. Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis Rheum 2002;46:1651-1660.
20. Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998;351:356-361.